Hepatitis C News and Research

Latest Hepatitis C News and Research

Vaccine confidence: an interview with Dr Heidi Larson

Here at the London School of Hygiene and Tropical Medicine we are running a project called the Vaccine Confidence Project and we have a global surveillance monitoring information around the world on media, social media, all sorts of information, reports from governments, UN, other sources, looking for any what we call “signals” of public distrust or concerns that come up.

30 Jan 2013

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

Molecular biologist Michael Karin is to receive this year's Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. The award, which carries CHF 100,000 in prize money, is considered one of the highest accolades for cancer researchers worldwide. The awards ceremony takes place in Zurich this Thursday in the framework of an international symposium on "Breakthroughs in Cancer Research and Therapy".

30 Jan 2013

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Medivir AB today announced a non-exclusive collaboration between Janssen Pharmaceuticals Inc. (Janssen) and Idenix Pharmaceuticals for the clinical development of an all-oral (interferon-free) direct-acting antiviral (DAA) hepatitis C (HCV) combination therapy.

29 Jan 2013

Shorter surveillance intervals detect HCC earlier

Hepatocellular carcinoma surveillance in at-risk patients at intervals of less than 6 months picks up smaller tumors compared with longer intervals, show two recently published studies.

28 Jan 2013

Tattooing poses HCV risk

Hepatitis C virus infection is more common in people who have had a tattoo, research shows.

21 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

New compounds can target RNase H enzyme in HIV

Scientists who study HIV are facing a troubling consequence of their own success. They created drugs that can now give infected patients almost normal life expectancy. However, those same drugs will eventually cause the constantly mutating virus to evolve into a form that eludes current treatments.

18 Jan 2013

Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis

Viruses prompt oncogenic transformation by genetically altering infected cells. Several recent studies have demonstrated that viruses alter the expression of microRNAs, non-coding RNA molecules that can block the expression of target genes.

17 Jan 2013

Early hepatitis B vaccination may be ineffective in teenagers

Research reveals that many infants who receive the complete series of hepatitis B virus vaccinations have lost their protection by the time they reach adolescence.

14 Jan 2013

Public health school deans condemn CIA's use of fake vaccination campaign in letter to Obama

"The deans of the nation's top public health schools sent a letter to President Obama on Monday condemning the Central Intelligence Agency's use of a vaccination campaign ruse in the hunt for Osama bin Laden," the New York Times reports.

9 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Newly discovered gene predicts HCV interferon response

Researchers have discovered a gene which interferes with the clearance of hepatitis C virus infection.

7 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Banning thimerosal from vaccines could hinder achievements in global childhood immunization

"Thanks to a herculean effort by health advocates, 78 percent of children in low-income countries receive the basic set of childhood vaccines, covering diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenza," a Bloomberg View editorial states.

3 Jan 2013

Few hepatitis C patients receive complete treatment

Less than 10% of patients with hepatitis C receive the treatment they need to achieve a sustained virologic response, results from a systematic review show.

31 Dec 2012

Hepatitis C virus takes over invaded cell by hijacking protein making machinery

Researchers at the University of Colorado School of Medicine have figured out intimate details of how the hepatitis C virus takes over an invaded cell, a breakthrough that could point to way for new treatments for the virus.

29 Dec 2012

SVR associated with prolonged overall survival in patients with chronic HCV infection

Among patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (development of excess fibrous connective tissue), sustained virological response (SVR) to interferon-based treatment was associated with a lower risk of all-cause mortality compared with patients without SVR, according to a study in the December 26 issue of JAMA.

26 Dec 2012

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides, Inc., announced today that it has received the final tranche of $2.5M from Seaside 88, LP, thereby completing the total of a $5M financing. This raise, and the receipt of the initial $2.5M tranche, was previously announced on June 29, 2012.

25 Dec 2012

Blogs respond to attacks against polio workers in Pakistan

The following blog posts were published in response to a series of attacks against polio workers in Pakistan this week, which have left eight dead since Monday.

21 Dec 2012

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Medivir AB today announced top-line results from three pivotal phase III trials examining the one pill, once-daily, investigational protease inhibitor, simeprevir (TMC435), administered with pegylated interferon and ribavirin.

20 Dec 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

Vaccine confidence: an interview with Dr Heidi Larson

UCSD molecular biologist to receive Charles Rodolphe Brupbacher Prize for Cancer Research

Janssen, Medivir and Idenix partner for clinical development of HCV combination therapy

Shorter surveillance intervals detect HCC earlier

Tattooing poses HCV risk

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

New compounds can target RNase H enzyme in HIV

Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis

Early hepatitis B vaccination may be ineffective in teenagers

Public health school deans condemn CIA's use of fake vaccination campaign in letter to Obama

Adolescents may lose hepatitis B virus protection despite vaccination as infants

Newly discovered gene predicts HCV interferon response

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

Banning thimerosal from vaccines could hinder achievements in global childhood immunization

Few hepatitis C patients receive complete treatment

Hepatitis C virus takes over invaded cell by hijacking protein making machinery

SVR associated with prolonged overall survival in patients with chronic HCV infection

NanoViricides to advance influenza drug candidate with completed $5M funding

Blogs respond to attacks against polio workers in Pakistan

Top-line results from Medivir's simeprevir phase III trials on genotype 1 HCV infection

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in